TEMPLE CITY, Calif., Feb. 08, 2017 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) (“Fulgent Genetics” or the “company”) today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, February 27, 2017 . The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host an investment community conference call the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investor section of the company’s website, www.fulgentgenetics.com, and through a live conference call by calling 1-855-321-9535, passcode # 65226206. An audio replay will be available in the investors section of the company’s website or by calling 1-855-859-2056 through March 6, 2017.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 275 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contacts: The Blueshirt Group Bob Jones, 212-871-5570, bob@blueshirtgroup.com Chris Danne, 415-217-5865, chris@blueshirtgroup.com
